Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etaracizumab ± Dacarbazine in Metastatic Melanoma
NCT00066196Phase 2Completed
- Sponsor
- MedImmune
- Start
- Aug 2003
- Primary completion
- Apr 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of etaracizumab in melanoma, sponsored by MedImmune. Started Aug 2003; status: completed.
02
Drugs
etaracizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00066196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00066196.